Study of XNW5004 Tablets in Advanced Prostate Cancer

Conditions

• Advanced Prostate Cancer

Interventions

• DRUG: XNW5004 1200 mg BID in Combination with Abiraterone plus Prednisone
• DRUG: XNW5004 1200 mg BID in Combination with Docetaxel plus Prednisone
• DRUG: XNW5004 800 mg or 1200 mg (1:1 randomization), PO, BID; Abiraterone 1000 mg PO, taken on an empty stomach at least 1 hour before and at least 2 hours after a meal, QD; plus Prednisone 5 mg PO BID
• DRUG: XNW5004 800 mg or 1200 mg (1:1 randomization), PO, BID; Abiraterone 1000 mg PO, taken on an empty stomach at least 1 hour before and at least 2 hours after a meal, QD; plus Prednisone 5 mg PO, QDD
• DRUG: XNW5004 800/1200 mg BID in Combination with Docetaxel plus Prednisone
• DRUG: XNW5004 1200 mg, PO, BID (10-14 hours interval between two doses, taken with warm water); Enzalutamide 160 mg, PO, QD. Each treatment cycle consists of 4 weeks.
• DRUG: Subsequent development plans will be determined based on preliminary study results.

Sponsor

Evopoint Biosciences Inc.